checkAd

     128  0 Kommentare scPharmaceuticals to Present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference

    BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 3 at 11:20am EST.

    A live webcast of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

    About scPharmaceuticals
    scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

    Katherine Taudvin
    scPharmaceuticals Inc., 781-301-6706
    ktaudvin@scpharma.com

    Investors:
    Hans Vitzthum
    LifeSci Advisors, 617-430-7578
    hans@lifesciadvisors.com

    Media:
    Kate Coyle
    ICR Inc., 203-682-8210
    kate.coyle@icrinc.com





    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    scPharmaceuticals to Present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) - scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance …